Target-specific nucleic acid molecules comprising quinoline modifications

CN119032177APending Publication Date: 2024-11-26APTACURE THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029450.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-06-23
Filing Date
2023-06-25
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing osteosclerostin monoclonal antibodies have low efficacy and cardiovascular risks in clinical applications, resulting in limited use in the treatment of osteoporosis. It is necessary to improve the target binding of osteosclerostin-specific nucleic acid aptamers. Affinity to enhance therapeutic effect.

Method used

By introducing quinoline modifications into the nucleic acid aptamer, especially substitutions such as quinolin-2-yl and quinolin-5-yl at key sites of the osteosclerostin-specific aptamer APC001, it can improve its interaction with the target. Binding affinity of osteosclerostin.

Benefits of technology

Quinoline modification significantly improves the binding affinity of the nucleic acid aptamer to the target osteosclerostin, reaching dozens or even dozens of times of the unmodified aptamer, reducing the KD value, enhancing the therapeutic potential of the drug and reducing cardiovascular risk. risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000028_0000
    Figure 00000028_0000
  • Figure 00000028_0001
    Figure 00000028_0001
Patent Text Reader

Abstract

The invention relates to the field of biological medicine. Specifically, the invention relates to a target-specific nucleic acid molecule comprising a quinoline modification capable of increasing the binding affinity of the nucleic acid molecule to a target.
Need to check novelty before this filing date? Find Prior Art

Description

Target-specific nucleic acid molecules comprising quinoline modifications Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a target-specific nucleic acid molecule comprising a quinoline modification, wherein the quinoline modification can increase the binding affinity between the nucleic acid molecule and the target.

[0002] Background of the Invention

[0003] Aptamers are single-stranded DNA or RNA that can form a complementary structure with the target. They have specificity and affinity comparable to monoclonal antibody drugs, while also having the advantages of being non-immunogenic, easy to produce, low cost, and thermally stable.

[0004] Sclerostin is a negative regulator of bone formation, making it an ideal target for drug development to promote bone formation and treat osteoporosis and other related diseases. Furthermore, studies have shown that sclerostin plays a crucial role in the development and progression of conditions such as osteogenesis imperfecta, hypophosphatemic rickets, and triple-negative breast cancer, making it a promising therapeutic target for these conditions. Romosozumab, an anti-sclerostin monoclonal antibody, promotes bone formation and has been approved by regulatory agencies in the United States, Europe, and Asia for postmenopausal women with osteoporosis at high risk of fracture. Due to the significant cardiovascular risks associated with sclerostin monoclonal antibody, the US Food and Drug Administration (FDA) requires that patients and their physicians assess the benefits of bone therapy against the cardiovascular risks before using it, and that use is limited to one year. The European Medicines Agency (EMA) has further tightened restrictions, requiring that patients at high risk of osteoporotic fractures who use sclerostin monoclonal antibody to have no prior history of cardiovascular disease.

[0005] The sclerostin protein has three structural regions: loop 1, loop 2, and loop 3. Among them, sclerostin monoclonal antibodies mainly act on loop 2. Studies have found that loop 2 is involved in both bone formation inhibition and cardiovascular protection, while sclerostin loop 3 is only involved in bone formation inhibition but not cardiovascular protection. Therefore, a nucleic acid aptamer specifically targeting sclerostin loop 3, APC001, was screened through SELEX technology, and the aptamer was verified to have the therapeutic potential to promote bone anabolism without increasing the risk of cardiovascular disease in the treatment of osteoporosis models and osteogenesis imperfecta models. This therapeutic aptamer received orphan drug designation from the US FDA for osteogenesis imperfecta in 2019 (FDA, DRU-2019-6966).

[0006] Improving the affinity of aptamers for their targets can help overcome the bottleneck of aptamer drug development, which often leads to low efficacy. Currently, the affinity of the aptamer APC001 for sclerostin (KD = 39.9 nM) is lower than that of the monoclonal antibody for sclerostin (KD = 0.12 nM). Therefore, to further enhance the aptamer's ability to inhibit sclerostin (even exceeding that of the monoclonal antibody), effective measures are necessary to increase its affinity for the target sclerostin.

[0007] Previous studies have shown that hydrophobic modification of aptamers can improve their affinity for their targets. Developing new aptamer modification methods and expanding the chemical diversity of aptamers are crucial for their further clinical application.

[0008] Summary of the Invention

[0009] The present invention provides at least the following embodiments:

[0010] Embodiment 1. A modified target-specific nucleic acid molecule comprising one or more quinoline-modified nucleotides, wherein the modified target-specific nucleic acid molecule has an increased binding affinity to a target compared to a corresponding control nucleic acid molecule.

[0011] Embodiment 2. The modified target-specific nucleic acid molecule of embodiment 1, wherein the nucleic acid molecule is selected from aptamers, antisense nucleic acids (antisense RNA), and dsRNA (such as siRNA and shRNA).

[0012] Embodiment 3. The modified target-specific nucleic acid molecule of embodiment 1 or 2, wherein the binding affinity of the modified target-specific nucleic acid molecule to the target is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more compared to the corresponding control nucleic acid molecule; or the binding affinity of the modified target-specific nucleic acid molecule to the target is at least about 1.5 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 16 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 75 times, at least about 100 times or more than the affinity of the corresponding unmodified nucleic acid molecule.

[0013] Embodiment 4. The modified target-specific nucleic acid molecule of any one of embodiments 1-3, wherein the modified target-specific nucleic acid molecule has a KD (dissociation constant) for the target of less than 100 nM, preferably less than 50 nM, preferably less than 40 nM, preferably less than 30 nM, preferably less than 20 nM, preferably less than 10 nM, preferably less than 5 nM or less.

[0014] Embodiment 5. The modified target-specific nucleic acid molecule of any one of embodiments 1-4, wherein the quinoline modification is quinoline-2-yl substitution, quinoline-3-yl substitution, quinoline-4-yl substitution, quinoline-5-yl substitution, quinoline-6-yl substitution, quinoline-7-yl substitution or quinoline-8-yl substitution, preferably, the quinoline modification is quinoline-5-yl substitution.

[0015] Embodiment 6. The modified target-specific nucleic acid molecule of any one of embodiments 1-5, wherein the quinoline-modified nucleotide comprises a substituent group R selected from the group consisting of:

[0016] Preferably,

[0017] Embodiment 7. The modified target-specific nucleic acid molecule of any one of embodiments 1-6, wherein the quinoline-modified nucleotide comprises a base portion of the following formula I:

[0018] in

[0019] Preferably,

[0020] Embodiment 8. The modified target-specific nucleic acid molecule of any one of Embodiments 1-7, wherein the quinoline-modified nucleotide comprises the structure of Formula II below:

[0021] in

[0022] Preferably,

[0023] Embodiment 9. The modified target-specific nucleic acid molecule of any one of embodiments 1-8, wherein one or more naturally occurring nucleotides in the target-specific nucleic acid molecule are substituted with the quinoline-modified nucleotide.

[0024] Embodiment 10. The modified target-specific nucleic acid molecule according to any one of embodiments 1 to 9, wherein the target-specific nucleic acid molecule may further comprise one or more modifications that extend its half-life in vivo.

[0025] Embodiment 11. The modified target-specific nucleic acid molecule according to any one of embodiments 1-10, wherein the modified target-specific nucleic acid molecule is a modified osteosclerostin-specific aptamer.

[0026] Embodiment 12. The modified target-specific nucleic acid molecule of embodiment 11, wherein the modified sclerostin-specific aptamer is derived from the sclerostin-specific aptamer of SEQ ID NO: 2.

[0027] Embodiment 13. The modified target-specific nucleic acid molecule of embodiment 12, wherein the modified sclerostin-specific aptamer has the nucleotide at one or more positions corresponding to SEQ ID NO: 2 selected from the group consisting of position 1, position 2, position 3, position 4, position 5, position 6, position 8, position 11, position 13, position 15, position 29, position 30, position 31, position 32, position 33, position 34, position 35, position 36, position 37, position 38, position 39, and position 40 replaced by the quinoline-modified nucleotide.

[0028] Embodiment 14. The modified target-specific nucleic acid molecule of embodiment 12 or 13, wherein one or more nucleotides corresponding to positions 6, 8, 11, 13, 32, and / or 34 of SEQ ID NO: 2 are substituted with the quinoline-modified nucleotides in the modified osteosclerostin-specific nucleic acid molecule.

[0029] Embodiment 15. The modified target-specific nucleic acid molecule of any one of embodiments 12-14, wherein the modified osteosclerostin-specific nucleic acid molecule comprises a nucleotide sequence selected from SEQ ID NOs: 3-23, wherein x is the quinoline-modified nucleotide.

[0030] Embodiment 16. The modified target-specific nucleic acid molecule of any one of embodiments 12-15, wherein the modified osteosclerostin-specific nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 8, 10, 11, 16, and 18, wherein x is the quinoline-modified nucleotide.

[0031] Embodiment 17. The modified target-specific nucleic acid molecule of any one of Embodiments 12-16, wherein the quinoline-modified nucleotide comprises the structure of Formula II below:

[0032] in,

[0033] Embodiment 18. A composition comprising the modified target-specific nucleic acid molecule of any one of embodiments 1-17, and optionally a pharmaceutically or physiologically acceptable carrier.

[0034] Embodiment 19. A method of increasing the binding affinity of a target-specific nucleic acid molecule to a target, the method comprising replacing one or more naturally occurring nucleotides in the target-specific nucleic acid molecule with one or more quinoline-modified nucleotides.

[0035] Embodiment 20. The method of embodiment 19, wherein the quinoline modification is quinolin-2-yl substitution, quinolin-3-yl substitution, quinolin-4-yl substitution, quinolin-5-yl substitution, quinolin-6-yl substitution, quinolin-7-yl substitution or quinolin-8-yl substitution, preferably, the quinoline modification is quinolin-5-yl substitution.

[0036] Embodiment 21. The method of embodiment 19 or 20, wherein the quinoline-modified nucleotide comprises a substituent group R selected from the group consisting of:

[0037] Preferably,

[0038] Embodiment 22. The method of any one of Embodiments 19-21, wherein the quinoline-modified nucleotide comprises a base portion of the following Formula I:

[0039] in

[0040] Preferably,

[0041] Embodiment 23. The method of any one of Embodiments 19-22, wherein the quinoline-modified nucleotide comprises the structure of Formula II below:

[0042] in

[0043] Preferably,

[0044] Embodiment 24. The method of any one of embodiments 19-23, wherein the one or more quinoline-modified nucleotide substitutions are introduced during chemical synthesis of the target-specific nucleic acid molecule.

[0045] Embodiment 25. The method of embodiment 24, wherein a modified phosphoramidite monomer selected from the group consisting of 2a-2g below is added during chemical synthesis of the target-specific nucleic acid molecule:

[0046] Embodiment 26. A modified phosphoramidite monomer selected from the following 2a-2g, for use in increasing the binding affinity of a target-specific nucleic acid molecule to a target:

[0047] BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1. Binding ability assays of sclerostin aptamers modified with different quinoline subtypes at key sites. Key sites are highlighted in the sequence. The horizontal axis of the heatmap represents the key sites modified with quinoline, while the vertical axis represents the different quinoline subtypes. Binding ability was assessed using the ELONA (Enzyme Ligated OligoNucleotide Assay) method.

[0049] Figure 2. Biolayer interferometry (BLI) results for determining the affinity of quinoline-modified aptamers for their targets. a) Binding and dissociation curves for each aptamer-target interaction. b) Equilibrium dissociation constant (KD) values ​​calculated from the final fitting.

[0050] Detailed Description of the Invention

[0051] Unless otherwise indicated or defined, all terms used have their ordinary meaning in the art, which will be understood by those skilled in the art. Reference is made, for example, to standard manuals such as Sambrook et al., "Molecular Cloning: A Laboratory Manual"; Lewin, "Genes VIII"; and Roitt et al., "Immunology" (8th edition), as well as to the general prior art cited herein; in addition, unless otherwise indicated, all methods, steps, techniques and operations not specifically described in detail can and have been performed in a manner known per se, which will be understood by those skilled in the art. Reference is also made, for example, to standard manuals, the above-mentioned general prior art and other references cited therein.

[0052] I. Modified Target-Specific Nucleic Acid Molecules with Improved Binding Affinity

[0053] In one aspect, the present invention provides a modified target-specific nucleic acid molecule comprising one or more quinoline-modified nucleotides, wherein the modified target-specific nucleic acid molecule has an increased binding affinity to the target compared to a corresponding control nucleic acid molecule. In some embodiments, the corresponding control nucleic acid molecule is a target-specific nucleic acid molecule that does not comprise the one or more quinoline-modified nucleotides.

[0054] As used herein, a "target-specific nucleic acid molecule" refers to a nucleic acid molecule that can specifically bind to a specific target. The target includes, but is not limited to, proteins, nucleic acids, small molecules, and the like. The nucleic acid molecule includes, but is not limited to, aptamers, antisense nucleic acids (antisense RNA), and dsRNA (e.g., siRNA, shRNA), preferably an aptamer.

[0055] In some embodiments, the modified target-specific nucleic acid molecule has an increased binding affinity for the target by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, or more compared to a corresponding control nucleic acid molecule. In some embodiments, the modified target-specific nucleic acid molecule has an affinity for the target that is at least about 1.5 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 16 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 75 times, at least about 100 times, or more than the affinity of the unmodified corresponding nucleic acid molecule. The binding affinity can be determined, for example, by enzyme-linked oligonucleotide assay (ELONA) or by biolayer interferometry (BLI).

[0056] In some embodiments, the modified target-specific nucleic acid molecule has a KD (dissociation constant) for the target of less than 100 nM, preferably less than 50 nM, preferably less than 40 nM, preferably less than 30 nM, preferably less than 20 nM, preferably less than 10 nM, preferably less than 5 nM or less. The KD is determined, for example, by enzyme-linked oligonucleotide assay (ELONA) or by biolayer interferometry (BLI).

[0057] In some embodiments, the quinoline modification is quinolin-2-yl substitution, quinolin-3-yl substitution, quinolin-4-yl substitution, quinolin-5-yl substitution, quinolin-6-yl substitution, quinolin-7-yl substitution, or quinolin-8-yl substitution. In some preferred embodiments, the quinoline modification is quinolin-5-yl substitution. The substitution positions on the quinoline are numbered as shown below:

[0058] In some embodiments, the quinoline-modified nucleotide comprises a substituent group R selected from the group consisting of:

[0059] In some preferred embodiments,

[0060] In some embodiments, the quinoline-modified nucleotide comprises the substituent group R in its base portion. In some embodiments, the quinoline-modified nucleotide is derived from uridine, such as deoxyuridine.

[0061] In some embodiments, the quinoline-modified nucleotide comprises a base moiety of the following Formula I:

[0062] in

[0063] In some preferred embodiments,

[0064] In some embodiments, the quinoline-modified nucleotide comprises the structure of Formula II below:

[0065] in

[0066] In some preferred embodiments,

[0067] In some embodiments, one or more nucleotides (natural nucleotides) in the target-specific nucleic acid molecule are substituted with the quinoline-modified nucleotides.

[0068] In some embodiments, the target-specific nucleic acid molecule may further comprise one or more modifications that extend its half-life in vivo.

[0069] The modifications that extend its in vivo half-life include, for example, modifications at the 3' and 5' ends, such as 3' and 5' capping. In some embodiments, the aptamer is capped at the 3' end with inverted deoxythymidine, ie, 3' inverted deoxythymidine (3'idT) modification.

[0070] The modification that extends its half-life in vivo can also include replacing one or more naturally occurring nucleotides with modified nucleotides. For example, the modified nucleotides for extending the half-life include but are not limited to nucleotides modified with 2'-fluoro, 2'-methoxyethyl, 2'-methoxy and / or 2'propyleneoxy groups (i.e., the 2' position hydroxyl group of ribose is replaced by fluoro, methoxyethyl, methoxy or propyleneoxy groups). The modified nucleotides for extending the half-life can also include C-5 modified pyrimidines. The term "C-5 modified pyrimidine" refers to a pyrimidine with a modification at the C-5 position. C-5 modified pyrimidines can enhance the nuclease resistance of oligonucleotides and are known in the art, for example, as described in International Patent Application WO 2011 / 130195 and the literature cited therein.

[0071] The modifications used to extend the half-life also include internucleotide modifications, such as internucleotide modifications with uncharged bonds (such as methylphosphonate, phosphotriester, phosphoamine, carbamate, etc.) and internucleotide modifications with charged bonds (such as phosphorothioate, phosphorodithioate, etc.), internucleotide modifications with intercalators (such as acridine, psoralen, etc.), internucleotide modifications containing chelators (such as metals, radioactive metals, boron, oxidizing metals, etc.), internucleotide modifications containing alkylating agents and internucleotide modifications with modified bonds (such as alpha anomeric nucleic acids, etc.).

[0072] The modification for extending the half-life may also include polyethylene glycol modification (PEG modification).

[0073] In another aspect, the present invention also provides a composition, such as a pharmaceutical composition, comprising a modified target-specific nucleic acid molecule of the present invention. In some embodiments, the composition further comprises a pharmaceutically or physiologically acceptable carrier or excipient. The composition can be used, for example, to detect the target, or to diagnose and / or treat a disease associated with the target.

[0074] In another aspect, the present invention provides a method for increasing the binding affinity of a target-specific nucleic acid molecule to a target, the method comprising replacing one or more naturally occurring nucleotides in the target-specific nucleic acid molecule with one or more quinoline-modified nucleotides, wherein the quinoline-modified nucleotides are as defined above.

[0075] In some embodiments, the nucleotide substitutions are introduced during chemical synthesis (eg, solid phase) of the target-specific nucleic acid molecule.

[0076] In some embodiments, a modified phosphoramidite monomer selected from the following 2a-2g is added during the chemical synthesis of the target-specific nucleic acid molecule:

[0077] In another aspect, the present invention also provides a modified phosphoramidite monomer selected from the following 2a-2g, which is used to increase the binding affinity of a target-specific nucleic acid molecule to a target:

[0078] II. Modified Sclerostin-Specific Nucleic Acid Molecules with Improved Binding Affinity

[0079] In some embodiments of the present invention, the target-specific nucleic acid molecule is a sclerostin-specific nucleic acid molecule. Therefore, the present invention also provides a modified sclerostin-specific nucleic acid molecule comprising one or more quinoline-modified nucleotides as described above.

[0080] In some embodiments, the target is sclerostin, such as human sclerostin. An exemplary human sclerostin comprises the amino acid sequence:

[0081] In some embodiments, the target-specific nucleic acid molecule is an aptamer that specifically binds to sclerostin (a modified sclerostin-specific aptamer). In some embodiments, the aptamer that specifically binds to sclerostin (unmodified) comprises the nucleotide sequence:

[0082] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3' (SEQ ID NO: 2).

[0083] In some embodiments, the modified sclerostin-specific aptamer has the nucleotide at one or more positions corresponding to SEQ ID NO: 2 selected from the group consisting of position 1, 2, 3, 4, 5, 6, 8, 11, 13, 15, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, and 40 replaced with the quinoline-modified nucleotide.

[0084] In some preferred embodiments, the modified sclerostin-specific nucleic acid molecule has the nucleotides at positions 6, 8, 11, 13, 32, and / or 34 corresponding to SEQ ID NO: 2 replaced by the quinoline-modified nucleotides.

[0085] In some embodiments, the modified sclerostin-specific nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:

[0086] 5'-xGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3' (SEQ ID NO: 3),

[0087] 5'-CxGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3' (SEQ ID NO: 4),

[0088] 5'-CGxGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3' (SEQ ID NO: 5),

[0089] 5'-CGGxGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3' (SEQ ID NO: 6),

[0090] 5’-CGGGxTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3’(SEQ ID NO:7),

[0091] 5’-CGGGGxGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3’(SEQ ID NO:8),

[0092] 5’-CGGGGTGxGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3’(SEQ ID NO:9),

[0093] 5’-CGGGGTGTGGxTTCGTCGTTAGCTTGATTTGGCAGCTGCC-3’(SEQ ID NO:10),

[0094] 5’-CGGGGTGTGGGTxCGTCGTTAGCTTGATTTGGCAGCTGCC-3’(SEQ ID NO:11),

[0095] 5’-CGGGGTGTGGGTTCxTCGTTAGCTTGATTTGGCAGCTGCC-3’(SEQ ID NO:12),

[0096] 5’-CGGGGTGTGGGTTCGTCGTTAGCTTGATxTGGCAGCTGCC-3’(SEQ ID NO:13),

[0097] 5’-CGGGGTGTGGGTTCGTCGTTAGCTTGATTxGGCAGCTGCC-3’(SEQ ID NO:14),

[0098] 5’-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTxGCAGCTGCC-3’(SEQ ID NO:15),

[0099] 5’-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGxCAGCTGCC-3’(SEQ ID NO:16),

[0100] 5’-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGxAGCTGCC-3’(SEQ ID NO:17),

[0101] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCxGCTGCC-3' (SEQ ID NO: 18),

[0102] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAxCTGCC-3' (SEQ ID NO: 19),

[0103] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGxTGCC-3' (SEQ ID NO: 20),

[0104] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCxGCC-3' (SEQ ID NO: 21),

[0105] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTxCC-3' (SEQ ID NO: 22),

[0106] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGxC-3' (SEQ ID NO: 23), and

[0107] 5'-CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCx-3' (SEQ ID NO: 24),

[0108] wherein x is the quinoline-modified nucleotide.

[0109] In some embodiments, the modified sclerostin-specific nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 8, wherein x is the quinoline-modified nucleotide. In some embodiments, the modified sclerostin-specific nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 10, wherein x is the quinoline-modified nucleotide. In some embodiments, the modified sclerostin-specific nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 11, wherein x is the quinoline-modified nucleotide. In some embodiments, the modified sclerostin-specific nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 16, wherein x is the quinoline-modified nucleotide. In some embodiments, the modified sclerostin-specific nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 18, wherein x is the quinoline-modified nucleotide.

[0110] In some preferred embodiments, the quinoline-modified nucleotide comprises the structure of Formula II below:

[0111] in,

[0112] In some embodiments, the modified sclerostin-specific nucleic acid molecule of the present invention has a binding affinity for sclerostin that is at least about 1.5 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 16 times, or more greater than the affinity of the unmodified sclerostin-specific nucleic acid molecule set forth in SEQ ID NO: 2. The binding affinity can be determined, for example, by enzyme-linked oligonucleotide assay (ELONA) or by biolayer interferometry (BLI).

[0113] In some embodiments, the modified sclerostin-specific nucleic acid molecule has a KD (dissociation constant) for sclerostin of less than 10 nM or even less than 5 nM, for example, as determined by enzyme-linked oligonucleotide assay (ELONA) or biolayer interferometry (BLI).

[0114] In another aspect, the present invention further provides a composition comprising the modified sclerostin-specific nucleic acid molecule of the present invention and, optionally, a pharmaceutically or physiologically acceptable carrier. The composition is used, for example, for detecting sclerostin, or for diagnosing and / or treating sclerostin-related diseases.

[0115] In another aspect, the present invention also provides a method for treating a disease by using the modified sclerostin-specific nucleic acid molecule of the present invention, which comprises administering a therapeutically effective amount of the modified sclerostin-specific nucleic acid molecule of the present invention to a subject in need thereof.

[0116] The disease is, for example, a sclerostin-related disease, such as a sclerostin-mediated disease.

[0117] As used herein, "sclerostin-associated diseases" include conditions in which bone mineral density (BMD) is abnormal and / or pathologically low relative to healthy subjects. Diseases characterized by low BMD and / or bone fragility include, but are not limited to, primary and secondary osteoporosis, osteopenia, osteomalacia, osteogenesis imperfecta (OI), avascular necrosis (osteonecrosis), bone fractures and implant healing (dental implants and hip implants), bone loss due to other conditions (e.g., associated with HIV infection, cancer, and arthritis). Other "sclerostin-associated diseases" include, but are not limited to, hypophosphatemic rickets, rheumatoid arthritis, osteoarthritis, arthritis, and osteolytic lesions.

[0118] As used herein, "sclerostin-related disease" includes sclerostin-related cancers, such as myeloma (e.g., multiple myeloma with osteolytic lesions), breast cancer (e.g., triple-negative breast cancer), colon cancer, melanoma, hepatocellular carcinoma, epithelial cancer, esophageal cancer, brain cancer, lung cancer, prostate cancer, or pancreatic cancer, and any metastases thereof.

[0119] "Sclerostin-related diseases" may also include renal diseases and cardiovascular diseases caused by at least the expression of sclerostin in the kidney and in the cardiovascular system. Such conditions include, but are not limited to, renal diseases such as the following: glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular damage associated with systemic diseases such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, polycystic kidney disease, neoplasia, sickle cell disease, and chronic inflammation), renal tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic kidney disease, medullary spongiosa renal, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug- and toxin-induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy), acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, gout, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic nephropathy, diffuse cortical necrosis, and renal infarction), or tumors (e.g., renal cell carcinoma and nephroblastoma).

[0120] The sclerostin-related diseases also include, but are not limited to, cardiovascular diseases such as ischemic heart disease (e.g., angina pectoris, myocardial infarction, and chronic ischemic heart disease), hypertensive heart disease, cor pulmonale, valvular heart disease (e.g., rheumatic fever and rheumatic heart disease, endocarditis, mitral valve prolapse, and aortic valve stenosis), congenital heart disease (e.g., valve and vascular occlusive lesions, atrial or ventricular septal defects, and persistent ductus arteriosus), or cardiomyopathy (e.g., myocarditis, congestive cardiomyopathy, and hypertrophic cardiomyopathy).

[0121] As used herein, "treating" a subject having a disease means that the subject's symptoms are partially or completely alleviated, or remain unchanged after treatment. Thus, treatment includes prevention, treatment, and / or cure. Prevention refers to preventing the underlying disease and / or preventing the worsening of symptoms or the development of the disease.

[0122] As used herein, a "therapeutically effective amount" or "therapeutically effective dose" refers to an amount of a substance, compound, material, or composition comprising a compound that is at least sufficient to produce a therapeutic effect after administration to a subject. Thus, it is the amount necessary to prevent, cure, ameliorate, arrest, or partially arrest the symptoms of a disease or condition. As used herein, "therapeutic effect" refers to an effect resulting from treatment of a subject that alters, typically ameliorates, or improves the symptoms of a disease or condition, or cures the disease or condition.

[0123] The dosage regimen for utilizing the nucleic acid molecule is selected based on a variety of factors, including, for example, the type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the specific nucleic acid molecule or salt thereof used. An ordinarily skilled physician can readily determine and prescribe the effective amount of the composition required to prevent, counter, or inhibit the progression of the condition. Example

[0124] Example 1. Synthesis routes of compounds 1a-1g and 2a-2g

[0125] 1) The structures of different quinoline subtype modified nucleosides (1a-1g) are as follows:

[0126] 2) Compounds 1a-1g react with phosphorus reagents to obtain different quinoline subtype-modified phosphoramidite monomers (2a-2g), which can be used as raw materials for solid-phase synthesis. The structures of 2a-2g are as follows:

[0127] 3) Synthesis routes of 1a-1g and 2a-2g:

[0128] Experimental part:

[0129] Synthesis of 1a-1g: To a 100 mL autoclave, add 5'-DMT-5-iododeoxyuracil (2.0 g, 3.0 mmol), aminomethylquinoline (0.95 g, 6.0 mmol), and tetrakis(triphenylphosphine)palladium (35 mg, 10% Pb). Subsequently, add 20 mL of anhydrous THF to dissolve the reactants, followed by the addition of Et3N (2.1 mL, 15 mmol). Cover the autoclave and open the pressure relief valve of the carbon monoxide cylinder. Displace the remaining airspace with carbon monoxide three times, then refill with carbon monoxide at a pressure of 0.30-0.40 MPa. Place the autoclave in an oil bath at 60-70°C and stir for 3-4 days. If the autoclave pressure drops below 0.30 MPa during this process, replenish carbon monoxide gas to maintain the pressure between 0.30-0.40 MPa. Place the autoclave in ice water for 20 minutes, then release the pressure in a fume hood. The autoclave was opened and the reaction mixture was poured into 100 ml of ice water and extracted three times with 50 ml of ethyl acetate. The organic phase was dried over anhydrous Na2SO4 and concentrated in vacuo. Next, the final product was purified using neutral silica with an eluent of n-hexane / ethyl acetate = 1 / 2. After concentration and evaporation to dryness, a sticky solid product was obtained (yields: 1a: 66%, 1b: 26%, 1c: 65%, 1d: 72%, 1e: 60%, 1f: 68%, 1g: 53%).

[0130] The NMR data are as follows:

[0131] 1a: 1 H NMR (400MHz, DMSO) δ11.98(s,1H),9.18(t,J=5.8Hz,1H),8.89(d,J=2.8Hz,1H),8.58(d,J=8. 5Hz,1H),8.54(s,1H),7.96(d,J=8.4Hz,1H),7.73–7.64(m,1H),7.56(d,J=7.0Hz,1H),7.49– 7.34(m,3H),7.23(tt,J=14.4,7.4Hz,7H),6.87(d,J=8.7Hz,4H),6.08(t,J=6.3Hz,1H),5.35(d,J=4.3Hz,1H),5.07 –4.89(m,2H),4.11(s,1H),3.97(d,J=4.0Hz,1H),3.68(d,J=3.7Hz,6H),3.20(d,J=15.7Hz,2H),2.39–2.14(m,2H). 13C NMR(101MHz,DMSO)δ163.7,161.9,158.5,150.7,149.9,148.5,146.2,145.3,136.0,135.8,132.4,130.3,130.2,129.5,129.1,128.3,128.1,127.1,126.4,121.8,113.7,105.4,86.7,86.5,86.3,70.9,64.1,55.4,39.93.

[0132] 1b: 1 H NMR(400MHz,DMSO)δ12.02(s,1H),9.27(t,J=6.0Hz,1H),8.86(dd,J=4.1,1.6Hz,1H),8.54(s,1H),8.21(d,J=7.8Hz,1H),7.97(d,J=8.7Hz,1H),7.81(s,1H),7.70(dd,J=8.7,1.7Hz,1H),7.48(dd,J=8.3,4.2Hz,1H),7.38(d,J=7.5Hz,2H),7.27(dd,J=8.7,4.3Hz,6H),7.13(t,J=7.3Hz,1H),6.87(dd,J=8.8,1.8Hz,4H),6.11(t,J=6.4Hz,1H),5.36(d,J=4.1Hz,1H),4.83–4.59(m,2H),4.11(s,1H),4.01–3.92(m,1H),3.68(s,6H),3.22(s,2H),2.37–2.18(m,2H). 13 C NMR(101MHz,DMSO)δ163.7,162.2,158.5,150.7,149.9,147.5,146.2,145.4,138.1,136.2,136.0,135.8,130.3,130.2,129.9,129.5,128.3,128.2,128.1,127.1,126.0,122.1,113.7,105.6,86.6,86.5,86.3,70.9,64.1,55.4,42.6.1c: 1H NMR(400MHz,DMSO)δ12.01(s,1H),9.29(t,J=6.1Hz,1H),8.88(dd,J=4.2,1.7Hz,1H),8.52(s,1H),8.33(d,J=8.2Hz,1H),7.92(d,J=8.7Hz,2H),7.55(dd,J=8.4,1.5Hz,1H),7.49(dd,J=8.3,4.2Hz,1H),7.37(d,J=7.5Hz,2H),7.33–7.21(m,6H),7.15(t,J=7.3Hz,1H),6.87(d,J=8.9Hz,4H),6.10(t,J=6.4Hz,1H),5.36(d,J=4.6Hz,1H),4.81–4.64(m,2H),4.12(dt,J=8.9,4.4Hz,1H),3.95(dd,J=8.8,4.4Hz,1H),3.69(d,J=3.4Hz,6H),3.21(t,J=7.9Hz,2H),2.37–2.16(m,2H). 13 C NMR(101MHz,DMSO)δ163.7,162.2,158.5,151.2,149.9,146.2,145.3,141.4,139.6,136.2,136.0,135.8,130.3,130.2,128.6,128.3,128.1,127.3,127.1,126.8,121.6,113.7,105.6,86.5,86.4,86.2,70.8,64.1,55.4,42.7.

[0133] 1d: 1H NMR(400MHz,DMSO)δ12.04(s,1H),9.29(t,J=5.9Hz,1H),8.77(d,J=4.4Hz,1H),8.54(s,1H),8.19(d,J=8.3Hz,1H),8.06(d,J=8.4Hz,1H),7.77(t,J=7.6Hz,1H),7.61(t,J=7.5Hz,1H),7.37(d,J=7.7Hz,2H),7.32(d,J=4.3Hz,1H),7.26(dd,J=11.1,6.7Hz,6H),7.16(t,J=7.2Hz,1H),6.85(d,J=8.5Hz,4H),6.10(t,J=6.3Hz,1H),5.36(d,J=4.4Hz,1H),5.09–4.94(m,2H),4.11(d,J=4.3Hz,1H),3.99–3.93(m,1H),3.65(d,J=4.7Hz,6H),3.20(d,J=4.0Hz,2H),2.38–2.20(m,2H). 13 C NMR(101MHz,DMSO)δ163.7,162.3,158.5,150.8,149.9,148.1,146.3,145.3,144.9,135.9,135.8,130.3,130.2,130.1,129.8,128.3,128.1,127.1,126.4,124.0,119.4,113.7,105.4,86.7,86.5,86.3,70.9,64.1,55.4,39.7.

[0134] 1e: 1H NMR(400MHz,DMSO)δ11.99(s,1H),9.28(t,J=6.1Hz,1H),8.89(t,J=3.1Hz,1H),8.50(s,1H),8.17(s,1H),8.01(d,J=8.4Hz,1H),7.85(d,J=8.1Hz,1H),7.75–7.69(m,1H),7.60–7.54(m,1H),7.36(d,J=7.5Hz,2H),7.28–7.22(m,6H),7.12(t,J=7.3Hz,1H),6.86(dd,J=8.9,1.8Hz,4H),6.08(t,J=6.4Hz,1H),5.37(d,J=4.5Hz,1H),4.78–4.63(m,2H),4.18–4.05(m,1H),3.95(dd,J=8.5,4.3Hz,1H),3.69(s,6H),3.18(t,J=4.7Hz,2H),2.33–2.17(m,2H). 13 C NMR(101MHz,DMSO)δ163.6,162.3,158.5,151.4,149.9,147.2,146.2,145.3,135.9,135.8,134.1,133.0,130.2,129.6,129.1,128.3,128.1,127.9,127.2,127.0,113.7,105.6,86.6,86.4,86.2,70.9,64.1,55.4,40.5.

[0135] 1f: 1H NMR(400MHz,DMSO)δ12.01(s,1H),9.65(t,J=5.4Hz,1H),8.52(s,1H),8.30(d,J=8.5Hz,1H),7.97(t,J=7.8Hz,2H),7.81–7.72(m,1H),7.59(dd,J=11.5,4.5Hz,1H),7.48(d,J=8.5Hz,1H),7.37(d,J=7.4Hz,2H),7.31–7.23(m,6H),7.15(t,J=7.3Hz,1H),6.87(d,J=8.9Hz,4H),6.11(t,J=6.4Hz,1H),5.36(d,J=4.6Hz,1H),4.79(d,J=5.4Hz,2H),4.13(dt,J=8.9,4.3Hz,1H),3.96(q,J=4.3Hz,1H),3.69(d,J=2.1Hz,6H),3.20(d,J=4.3Hz,2H),2.36–2.19(m,2H). 13 C NMR(101MHz, DMSO)δ163.6,162.1,158.6,158.5,150.0,146.1,145.3,137.1,136.0,135.8,130.3,130.2,128.9,128.4,128.3,128.1,127.4,127.1,126.7,120.2,113.7,105.7,86.5,86.4,86.2,70.8,64.1,55.4,45.3.

[0136] 1g: 1H NMR (400MHz, DMSO) δ11.93(s,1H),9.42(t,J=6.1Hz,1H),8.98(dd,J=4.2,1.7Hz,1H),8.48(s,1H),8.39(dt,J=8.6,4.3H z,1H),7.90(d,J=8.1Hz,1H),7.64(d,J=7.0Hz,1H),7.59(dd,J=8.3,4.2Hz,1H),7.56–7.50(m,1H),7.36(d,J=7.5Hz,2H ),7.30–7.22(m,6H),7.17(t,J=7.2Hz,1H),6.87(d,J=8.8Hz,4H),6.09(t,J=6.4Hz,1H),5.34(d,J=4.6Hz,1H),5.08(d, J=6.0Hz,2H),4.17–4.08(m,1H),3.94(q,J=4.4Hz,1H),3.68(d,J=3.7Hz,6H),3.19(d,J=4.4Hz,2H),2.35–2.11(m,2H). 13 C NMR (101MHz, DMSO) δ163.6,161.9,158.5,150.3,149.9,146.2,146.0,145.4,136.9,135.9,135.8,130.3, 130.1,128.4,128.3,128.1,127.8,127.1,126.7,122.0,113.7,105.8,86.4,86.3,86.2,70.8,64.1,55.4.

[0137] Synthesis of 2a-2g: Under nitrogen and in an ice-water bath, tetrazole (0.69 g, 9.8 mmol) and the phosphorus reagent 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite (2.9 g, 9.8 mmol) were added to a 50 mL solution of 3.3 mmol of 1a-1g (2.2 g for 1a, 2.4 g for 1b-1g) in anhydrous dichloromethane. The solution was then brought to room temperature and stirred for 2 hours before being concentrated in vacuo. The residue was then purified by flash chromatography (n-hexane / ethyl acetate = 1 / 1) to afford the desired products 2a-2g as viscous, pale yellow solids (yields: 2a: 70%, 2b: 72%, 2c: 48%, 2d: 70%, 2e: 58%, 2f: 79%, 2g: 52%).

[0138] 2a: 1H NMR(400MHz,DMSO)δ11.93(s,1H),9.18(d,J=5.8Hz,1H),8.89(s,1H),8.63–8.52(m,2H),7.95(d,J=8.4Hz,1H),7.73–7.63(m,1H),7.56(d,J=7.0Hz,1H),7.47–7.35(m,3H),7.30–7.23(m,6H),7.18(dd,J=7.6,5.9Hz,1H),6.86(d,J=7.9Hz,4H),6.13–6.04(m,1H),5.05–4.91(m,2H),4.40–4.29(m,1H),4.10(dd,J=15.9,4.1Hz,1H),3.70–3.67(m,6H),3.63–3.37(m,4H),3.23(d,J=3.8Hz,2H),2.75(t,J=5.9Hz,1H),2.64(t,J=5.4Hz,1H),2.47–2.35(m,2H),1.10(dd,J=15.1,7.7Hz,9H),0.96(d,J=6.7Hz,3H). 13 C NMR(101MHz,DMSO)δ163.7,161.9,158.5,150.7,149.8,148.5,146.7,146.5,145.2,136.0,135.9,135.8,135.7,132.4,130.2,129.5,129.2,128.3,128.1,127.1,126.4,121.8,119.4,119.2,113.7,105.5,87.1,86.3,85.6,73.2,63.7,59.0,58.8,55.4,43.1,43.0,24.7,20.2. 31 P NMR(162MHz,DMSO)δ147.6,147.3.

[0139] 2b: 1H NMR(400MHz,DMSO)δ11.93(s,1H),9.27(s,1H),8.85(d,J=2.9Hz,1H),8.57(d,J=7.0Hz,1H),8.21(t,J=8.2Hz,1H),7.96(d,J=8.6Hz,1H),7.80(s,1H),7.70(d,J=8.6Hz,1H),7.47(dd,J=7.4,3.2Hz,1H),7.37(d,J=7.3Hz,2H),7.25(t,J=6.3Hz,6H),7.16–7.11(m,1H),6.86(d,J=7.7Hz,4H),6.15–6.04(m,1H),4.70(s,2H),4.34(s,1H),4.15–4.05(m,1H),3.68(s,6H),3.61–3.46(m,4H),3.24(s,2H),2.75(t,J=5.8Hz,1H),2.64(d,J=6.1Hz,1H),2.47–2.38(m,2H),1.10(dd,J=14.7,7.5Hz,9H),0.96(d,J=6.7Hz,3H). 13 C NMR(101MHz,DMSO)δ163.7,162.2,158.5,150.7,149.8,147.5,146.6,146.4,145.2,138.1,136.2,135.9,135.8,135.7,130.2,130.1,129.8,129.5,128.3,128.2,128.1,127.1,126.0,122.1,119.4,119.2,113.7,105.6,87.0,86.4,85.6,73.4,63.7,59.0,58.7,55.4,43.1,42.6,24.7,20.2. 31 P NMR(162MHz,DMSO)δ147.7,147.4.

[0140] 2c: 1H NMR(400MHz,DMSO)δ11.92(s,1H),9.29(t,J=5.5Hz,1H),8.88(d,J=2.7Hz,1H),8.55(d,J=5.6Hz,1H),8.33(d,J=8.2Hz,1H),7.92(d,J=9.9Hz,2H),7.55(d,J=8.4Hz,1H),7.49(dd,J=8.2,4.2Hz,1H),7.41–7.33(m,2H),7.26(s,6H),7.15(t,J=7.2Hz,1H),6.86(dd,J=8.6,3.0Hz,4H), 6.16–6.04(m,1H),4.73(d,J=5.5Hz,2H),4.36(d,J=4.5Hz,1H),4.09(dd,J=9.2,4.2Hz,1H),3.69(d,J=1.4Hz,6H),3.63–3.39(m,4H),3.26(dd,J=12.2,7.2Hz,2H),2.75(t,J=5.8Hz,1H),2.64(t,J=5.5Hz,1H),2.42(dd,J=12.8,5.9Hz,2H),1.10(dd,J=14.3,7.4Hz,9H),0.96(d,J=6.7Hz,3H). 13 C NMR(101MHz,DMSO)δ163.7,162.2,158.5,151.2,149.9,148.3,146.6,146.5,145.2,141.4,136.2,135.9,135.8,135.7,130.2,130.1,128.6,128.3,128.1,127.3,127.1,126.8,121.6,119.4,119.2,113.7,105.6,87.0,86.3,85.5,73.5,63.8,59.0,58.8,55.4,43.1,42.7,24..7,20.2. 31 P NMR(162MHz,DMSO)δ147.7,147.4.

[0141] 2d: 1H NMR(400MHz,DMSO)δ11.94(s,1H),9.28(d,J=4.3Hz,1H),8.77(t,J=4.7Hz,1H),8.57(d,J=6.1Hz,1H),8.19(d,J=8.4Hz,1H),8.06(d,J=8.4Hz,1H),7.77(dd,J=8.2,7.1Hz,1H),7.65–7.56(m,1H),7.40–7.35(m,2H),7.33(t,J=4.2Hz,1H),7.26(dt,J=9.0,5.0Hz,6H),7.17(dd,J=7.7,5.9Hz,1H),6.85(dd,J=8.9,2.5Hz,4H),6.15–6.06(m,1H),5.02(s,2H),4.41–4.30(m,1H),4.14–4.07(m,1H),3.67–3.63(m,6H),3.61–3.46(m,4H),3.23(d,J=4.4Hz,2H),2.75(t,J=5.9Hz,1H),2.64(t,J=6.1Hz,1H),2.43(dd,J=13.1,7.6Hz,2H),1.13–1.07(m,9H),0.96(d,J=6.7Hz,3H). 13 C NMR(101MHz,DMSO)δ163.7,162.3,158.5,150.8,149.9,148.1,146.7,146.6,145.2,144.9,135.9,135.8,135.7,130.2,130.1,129.8,128.3,128.1,127.1,126.4,124.0,119.4,119.2,113.7,105.5,87.1,86.4,85.6,73.4,63.8,59.0,58.8,55.4,43.1,43.0,24.7,20.2. 31 P NMR(162MHz,DMSO)δ147.6,147.3.

[0142] 2e: 1H NMR(400MHz,DMSO)δ11.93(s,1H),9.30(t,J=5.6Hz,1H),8.89(s,1H),8.54(d,J=6.9Hz,1H),8.17(s,1H),8.01(d,J=8.4Hz,1H),7.85(t,J=7.7Hz,1H),7.72(t,J=7.6Hz,1H),7.57(t,J=7.3Hz,1H),7.40–7.33(m,2H),7.25(td,J=6.4,2.9Hz,6H),7.13(t,J=7.2Hz,1H),6.91–6.81(m,4H),6.13–6.02(m,1H),4.70(d,J=5.6Hz,2H),4.41–4.30(m,1H),4.14–4.07(m,1H),3.69(s,6H),3.62–3.46(m,4H),3.22(d,J=4.5Hz,2H),2.75(t,J=5.9Hz,1H),2.64(dd,J=6.1,4.7Hz,1H),2.48–2.35(m,2H),1.10(dd,J=15.3,7.7Hz,9H),0.96(d,J=6.7Hz,3H). 13 C NMR(101MHz,DMSO)δ163.6,162.3,158.5,151.4,149.9,147.2,146.6,146.4,145.2,135.9,135.8,135.7,134.1,133.0,130.2,129.6,129.1,128.3,128.1,127.9,127.2,119.4,119.2,113.7,105.6,87.0,86.3,85.6,73.4,63.7,58.8,55.4,43.1,43.0,24.7,20.2. 31 P NMR(162MHz,DMSO)δ147.6,147.3.

[0143] 2f: 1H NMR(400MHz,DMSO)δ12.01(s,1H),9.66(t,J=5.1Hz,1H),8.56(d,J=6.0Hz,1H),8.31(dd,J=8.5,2.8Hz,1H),8.00–7.93(m,2H),7.76(dd,J=11.3,4.2Hz,1H),7.58(t,J=7.5Hz,1H),7.48(dd,J=8.5,2.5Hz,1H),7.37(dd,J=7.5,3.1Hz,2H),7.29–7.23(m,6H),7.15(t,J=7.2Hz,1H),6.86(dd,J=8.9,3.0Hz,4H),6.16–6.05(m,1H),4.83–4.76(m,2H),4.38(dd,J=10.1,4.8Hz,1H),4.14–4.07(m,1H),3.69(d,J=2.4Hz,6H),3.63–3.46(m,4H),3.29–3.18(m,2H),2.76(t,J=5.9Hz,1H),2.68–2.61(m,1H),2.48–2.37(m,2H),1.13–1.07(m,9H),0.96(d,J=6.7Hz,3H). 13 C NMR(101MHz,DMSO)δ163.6,162.1,158.6,149.9,147.3,146.5,146.3,145.2,137.1,135.9,135.8,135.7,130.2,130.1,128.9,128.3,128.1,127.4,127.1,126.7,120.2,119.4,119.2,113.7,105.8,86.9,86.4,85.5,73.1,63.5,59.0,55.4,45.3,43.1,24.8,20.2. 31 P NMR(162MHz,DMSO)δ147.6,147.3.

[0144] 2g: 1H NMR (400MHz, DMSO) δ11.93(s,1H),9.42(t,J=5.7Hz,1H),8.98(d,J=2.7Hz,1H),8.51(d,J=5.7Hz,1H),8.40(d,J=7.0Hz,1H),7.91(d,J =8.1Hz,1H),7.68–7.56(m,2H),7.53(td,J=7.7,2.8Hz,1H),7.40–7.32(m,2H),7.31–7.21(m,6H),7.20–7.13(m,1H),6.86(dd,J=8.8,3 .5Hz,4H),6.14–6.03(m,1H),5.08(d,J=5.8Hz,2H),4.41–4.29(m,1H),4.13–4.05(m,1H),3.71–3.66(m,6H),3.62–3.38(m,4H),3.24(d d,J=25.5,5.9Hz,2H),2.75(t,J=5.9Hz,1H),2.66–2.61(m,1H),2.46–2.33(m,2H),1.09(dd,J=16.0,7.1Hz,9H),0.95(d,J=6.7Hz,3H). 13 C NMR (101MHz, DMSO) δ163.6,161.1,158.5,150.3,149.9,146.4,146.2,145.2,136.9,135.9,135.8,135.7,130.2,130.1,128.4,128.3,128.1, 127.8,127.1,126.7,122.0,119.4,119.2,113.7,105.9,86.9,86.4,85.5,72.9,63.6,59.0,55.4,43.1,43.0,24.7,20.2. 31 P NMR (162MHz, DMSO) δ147.7,147.3.

[0145] Example 2: Increasing target binding affinity of nucleic acid aptamer APC001 by quinoline modification

[0146] In previous work, the protein-SELEX technology was used to screen the aptamer APC001, which specifically targets sclerostin. The specific sequence is: CGGGGTGTGGGTTCGTCGTTAGCTTGATTTGGCAGCTGCC. Chemical and biological studies revealed 22 key aptamer-target binding sites (C1, G2, G3, G4, G5, T6, T8, G11, T13, G15, T29, T30, G31, G32, C33, A34, G35, C36, T37, G38, C39, and C40).

[0147] The present invention uses chemical modification techniques to modify different subtypes of quinoline at these key sites. First, different quinolines are coupled to nucleosides to obtain compounds 1a-1g. Compounds 1a-1g are then reacted with phosphorus reagents to construct phosphoramidite monomers 2a-2g modified with different quinoline subtypes. Finally, DNA solid-phase synthesis is used to obtain aptamers modified with quinoline at different key sites.

[0148] Specifically, phosphoramidite monomers 2a to 2g were inserted into the 22 key sites of the sclerostin aptamer using standard DNA solid-phase synthesis technology. The sequences and insertion positions are shown in Table 1 below:

[0149] Table 1. Quinoline modified aptamer sequences (x = a, b, c, d, e, f, g)

[0150] Comparison of the binding ability of various quinoline-modified aptamers to the target sclerostin using the ELONA method

[0151] Prepare the following buffers in advance:

[0152] ELONA B&W buffer: PBS, 1mM MgCl2, 0.05% Tween 20;

[0153] ELONA assay blocking buffer: PBS, 0.1% Tween 20 and 1% BSA;

[0154] ELONA assay washing buffer: PBS, 1mM MgCl2, 0.1% Tween 20 and 0.1% BSA;

[0155] ELONA assay Strep-HRP binding buffer: Strep-HRP diluted 1:10000 in ELONA assay washing buffer;

[0156] ELONA assay reaction stopping buffer:2M H2SO4.

[0157] Add 160 ng of target protein to each 96-well plate containing 100 μl of SELEX B&W buffer and incubate overnight at 4°C. The 96-well plate was then blocked with blocking buffer for 1 hour at room temperature and washed four times with SELEX B&W buffer. A 1 μM terminally biotinylated adaptor dissolved in 100 μl of SELEX B&W buffer was added to each well and incubated at room temperature for 45 minutes with gentle agitation. Next, wash four times with SELEX B&W buffer to remove nonspecific and very weak binding. Add 100 μl of Strap-HRP (1:10,000 dilution) to each well, incubate for 30 minutes, and wash four times with washing buffer. Add 50 μl of TMB to each well and incubate for 20 minutes. Terminate the reaction by adding 50 μl of 2 M H₂SO₄. Measure absorbance at 450 nm using a microplate reader.

[0158] The results are shown in Figure 1. The resulting quinoline-modified sclerostin aptamers generally exhibited enhanced target binding compared to native APC001. The most significant improvement (nearly 16-fold) was observed after 5-quinoline (d) modifications were made at positions 6 and 11 of the aptamers (i.e., aptamers APC001-d6 and APC001-d11).

[0159] Biolayer interferometry (BLI) was used to determine the affinity of quinoline-modified aptamers to their targets.

[0160] Biolayer interferometry (BLI) was used to determine the affinities of the six sequences with the highest binding abilities in Figure 1, namely APC001-d6, APC001-d8, APC001-d11, APC001-d13, APC001-d32, and APC001-d34.

[0161] The Octet 96 / 96e system (ForteBio) was used to analyze the interaction between the quinoline-modified aptamer and sclerostin. All operations were performed at room temperature. The program was run as follows:

[0162] Baseline: 1×PBS buffer (10mM phosphate buffer, 2.7mM KCl and 137mM NaCl, pH 7.4), 120s, 1000rpm;

[0163] Loading: 100nM 5-biotinated aptamer in 1×PBST buffer (1×PBS+0.02% Tween20, pH 7.4), 600s, 500rpm;

[0164] Baseline 2:1×PBST buffer,300s,500rpm;

[0165] Association: sclerostin (20nM, 16nM, 12nM, 8nM, 4nM, 0nM) in 1×PBST buffer, 600s, 500rpm;

[0166] Dissociation:1×PBST buffer,600s,500rpm;

[0167] Regenration: 5M NaCl, 30s, 500rpm;

[0168] Neutralization: 1×PBS buffer, 60s, 500rpm.

[0169] Finally, the equilibrium dissociation constant KD value was calculated using the analysis software ForteBio Data analysis 11.0 with a 1:1 binding mode fitting.

[0170] The results are shown in Figure 2. The quinoline structure in the present invention greatly improves the affinity between the aptamer and the target.

Claims

1. A modified target-specific nucleic acid molecule comprising one or more quinoline-modified nucleotides, wherein the modified target-specific nucleic acid molecule has an increased binding affinity to a target compared to a corresponding control nucleic acid molecule.

2. The modified target-specific nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is selected from the group consisting of an aptamer, an antisense nucleic acid (antisense RNA), and a dsRNA (such as siRNA, shRNA).

3. The modified target-specific nucleic acid molecule of claim 1 or 2, wherein the binding affinity of the modified target-specific nucleic acid molecule to the target is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, or more compared to a corresponding control nucleic acid molecule; or the binding affinity of the modified target-specific nucleic acid molecule to the target is at least about 1.5 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 16 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 75 times, at least about 100 times, or more than the affinity of the corresponding unmodified nucleic acid molecule.

4. The modified target-specific nucleic acid molecule of any one of claims 1 to 3, wherein the modified target-specific nucleic acid molecule has a KD (dissociation constant) for the target of less than 100 nM, preferably less than 50 nM, preferably less than 40 nM, preferably less than 30 nM, preferably less than 20 nM, preferably less than 10 nM, preferably less than 5 nM or less.

5. The modified target-specific nucleic acid molecule of any one of claims 1 to 4, wherein the quinoline modification is quinoline-2-yl substitution, quinoline-3-yl substitution, quinoline-4-yl substitution, quinoline-5-yl substitution, quinoline-6-yl substitution, quinoline-7-yl substitution or quinoline-8-yl substitution, preferably, the quinoline modification is quinoline-5-yl substitution.

6. The modified target-specific nucleic acid molecule of any one of claims 1 to 5, wherein the quinoline-modified nucleotide comprises a substituent group R selected from the group consisting of: Preferably, 7. The modified target-specific nucleic acid molecule of any one of claims 1 to 6, wherein the quinoline-modified nucleotide comprises a base portion of the following formula I: in Preferably, 8. The modified target-specific nucleic acid molecule of any one of claims 1 to 7, wherein the quinoline-modified nucleotide comprises a structure of Formula II below: in Preferably, 9. The modified target-specific nucleic acid molecule of any one of claims 1 to 8, wherein one or more naturally occurring nucleotides in the target-specific nucleic acid molecule are substituted with the quinoline-modified nucleotide.

10. The modified target-specific nucleic acid molecule according to any one of claims 1 to 9, wherein the target-specific nucleic acid molecule further comprises one or more modifications that extend its half-life in vivo.

11. The modified target-specific nucleic acid molecule according to any one of claims 1 to 10, wherein the modified target-specific nucleic acid molecule is a modified osteosclerostin-specific aptamer.

12. The modified target-specific nucleic acid molecule of claim 11, wherein the modified sclerostin-specific aptamer is derived from the sclerostin-specific aptamer of SEQ ID NO:

2.

13. The modified target-specific nucleic acid molecule of claim 12, wherein the modified sclerostin-specific aptamer is substituted with the quinoline-modified nucleotide at one or more positions corresponding to SEQ ID NO: 2 selected from the group consisting of position 1, position 2, position 3, position 4, position 5, position 6, position 8, position 11, position 13, position 15, position 29, position 30, position 31, position 32, position 33, position 34, position 35, position 36, position 37, position 38, position 39, and position 40.

14. The modified target-specific nucleic acid molecule of claim 12 or 13, wherein the modified osteosclerostin-specific nucleic acid molecule is substituted with the quinoline-modified nucleotide at one or more nucleotides corresponding to positions 6, 8, 11, 13, 32, and / or 34 of SEQ ID NO:

2.

15. The modified target-specific nucleic acid molecule of any one of claims 12 to 14, wherein the modified osteosclerostin-specific nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 3 to 24, wherein x is the quinoline-modified nucleotide.

16. The modified target-specific nucleic acid molecule of any one of claims 12 to 15, wherein the modified osteosclerostin-specific nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 8, 10, 11, 16, and 18, wherein x is the quinoline-modified nucleotide.

17. The modified target-specific nucleic acid molecule of any one of claims 12 to 16, wherein the quinoline-modified nucleotide comprises the structure of Formula II below: in, 18. A composition comprising the modified target-specific nucleic acid molecule of any one of claims 1 to 17, and optionally a pharmaceutically or physiologically acceptable carrier.

19. A method for increasing the binding affinity of a target-specific nucleic acid molecule to a target, the method comprising replacing one or more naturally occurring nucleotides in the target-specific nucleic acid molecule with one or more quinoline-modified nucleotides.

20. The method of claim 19, wherein the quinoline modification is quinolin-2-yl substitution, quinolin-3-yl substitution, quinolin-4-yl substitution, quinolin-5-yl substitution, quinolin-6-yl substitution, quinolin-7-yl substitution or quinolin-8-yl substitution, preferably, the quinoline modification is quinolin-5-yl substitution.

21. The method of claim 19 or 20, wherein the quinoline-modified nucleotide comprises a substituent group R selected from the group consisting of: Preferably, 22. The method of any one of claims 19-21, wherein the quinoline-modified nucleotide comprises a base portion of the following formula I: in Preferably, 23. The method of any one of claims 19-22, wherein the quinoline-modified nucleotide comprises a structure of Formula II: in Preferably, 24. The method of any one of claims 19-23, wherein the one or more quinoline-modified nucleotide substitutions are introduced during chemical synthesis of the target-specific nucleic acid molecule.

25. The method of claim 24, wherein a modified phosphoramidite monomer selected from the group consisting of 2a-2g below is added during chemical synthesis of the target-specific nucleic acid molecule:

26. A modified phosphoramidite monomer selected from the following 2a-2g, for use in increasing the binding affinity of a target-specific nucleic acid molecule to a target: